To suppress the fluorescence quenching of pyrene in the aggregation state, this article presents a facile strategy for the construction of pyrene-based aggregation-induced emission luminogens (AIEgens) via decorating the pyrene core with benzophenone units at the 1-, 2-or 2,7-positions. This set of pyrene-based compounds 1-3 displayed a weak deep blue fluorescence in solution, but an enhanced excimer emission with λ em max of 426-436 nm in the aggregation state. Interestingly, unlike reported benzophenone derivatives, this series of compounds did not exhibit thermally activated delayed fluorescence/ phosphorescent properties.
Pyrene derivatives with substituents at 2-or 2,7-positions have an exceptional electronic structure due to the nodal plane at these two positions. Herein, a series of linear-shaped pyrene derivatives 1-3 were designed and synthesized via combining (4-tert-butylphenyl)ethynyl & (4-tert-butylphenyl) substituents at 2-and 7-position by using the Pd-catalysis coupling reaction with high yield. The molecular structures are completely confirmed by 1 H/ 13 CNMR, high-resolution mass spectrometry, Xray single crystal diffraction technology, etc. Indeed, compared to reported arylethynyl substituents pyrenes, the 2,7-substituted molecules 2 and 3 exhibited a deep blue emission (CIE y < 0.04) with considerable quantum yield both in solution and in the solid-state. X-ray crystallographic results indicated that the molecular pattern has a considerable impact on the emission behavior of the synthesized derivatives. In addition, theoretical studies of compounds 1-3 were also preformed to understand the relationship between molecular structure and photophysical features.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.